Tumor-targeted nanomedicines for cancer theranostics

Pharmacological Research - Tập 115 - Trang 87-95 - 2017
Alexandra Arranja1,2, Vertika Pathak3, Twan Lammers3,2,4, Yang Shi3
1Department of Chemical Engineering, Delft University of Technology, 2629 HZ Delft, the Netherlands
2Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, 3584 CG, Utrecht, The Netherlands
3Department of Nanomedicines and Theranostics, Institute for Experimental Molecular Imaging (ExMI), RWTH Aachen University Clinic, 52074 Aachen, Germany
4Department of Targeted Therapeutics, MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, 7500 AE Enschede, The Netherlands

Tóm tắt

Từ khóa


Tài liệu tham khảo

Siegel, 2016, Cancer statistics, 2016, Cancer J. Clin., 66, 7, 10.3322/caac.21332

Cho, 2008, Therapeutic nanoparticles for drug delivery in cancer, Clin. Cancer Res., 14, 1310, 10.1158/1078-0432.CCR-07-1441

Northfelt, 1996, Doxorubicin encapsulated in liposomes containing surface-found polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma, J. Clin. Pharmacol., 36, 55, 10.1002/j.1552-4604.1996.tb04152.x

Abolhoda, 1999, Rapid activation of MDR1 gene expression in human metastatic sarcoma after in vivo exposure to doxorubicin, Clin. Cancer Res., 5, 3352

Trock, 1997, Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance, J. Natl. Cancer Inst., 89, 917, 10.1093/jnci/89.13.917

Leonard, 2003, The role of ABC transporters in clinical practice, Oncologist, 8, 411, 10.1634/theoncologist.8-5-411

Hile, 2010, Persistent mobility disability after neurotoxic chemotherapy, Phys. Ther., 90, 1649, 10.2522/ptj.20090405

Rugbjerg, 2014, Cardiovascular disease in survivors of adolescent and young adult cancer: a Danish cohort study, 1943–2009, J. Natl. Cancer Inst., 106, 10.1093/jnci/dju110

Aleman, 2007, Late cardiotoxicity after treatment for Hodgkin lymphoma, Blood, 109, 1878, 10.1182/blood-2006-07-034405

Moses, 2003, Advancing the field of drug delivery: taking aim at cancer, Cancer Cell, 4, 337, 10.1016/S1535-6108(03)00276-9

Maeda, 2013, The EPR effect for macromolecular drug delivery to solid tumors: improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo, Adv. Drug Deliv. Rev., 65, 71, 10.1016/j.addr.2012.10.002

Bertrand, 2014, Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology, Adv. Drug Deliv. Rev., 66, 2, 10.1016/j.addr.2013.11.009

Lammers, 2012, Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress, J. Control. Release, 161, 175, 10.1016/j.jconrel.2011.09.063

Kamaly, 2012, Targeted polymeric therapeutic nanoparticles: design: development and clinical translation, Chem. Soc. Rev., 41, 2971, 10.1039/c2cs15344k

Peer, 2007, Nanocarriers as an emerging platform for cancer therapy, Nat. Nanotechnol., 2, 751, 10.1038/nnano.2007.387

Farokhzadand, 2009, Impact of nanotechnology on drug delivery, ACS Nano, 3, 16, 10.1021/nn900002m

Bertrandand, 2012, The journey of a drug-carrier in the body: an anatomo-physiological perspective, J. Control. Release, 161, 152, 10.1016/j.jconrel.2011.09.098

Barenholz, 2012, Doxil®—the first FDA-approved nano-drug: lessons learned, J. Control. Release, 160, 117, 10.1016/j.jconrel.2012.03.020

Gabizon, 2003, Pharmacokinetics of pegylated liposomal doxorubicin—review of animal and human studies, Clin. Pharmacokinet., 42, 419, 10.2165/00003088-200342050-00002

Etheridge, 2013, The big picture on nanomedicine: the state of investigational and approved nanomedicine products, Nanomed. Nanotechnol., 9, 1, 10.1016/j.nano.2012.05.013

Kopecekand, 2010, HPMA copolymers: origins, early developments, present, and future, Adv. Drug Deliv. Rev., 62, 122, 10.1016/j.addr.2009.10.004

Cabraland, 2014, Progress of drug-loaded polymeric micelles into clinical studies, J. Control. Release, 190, 465, 10.1016/j.jconrel.2014.06.042

Ojha, 2015, Image-guided drug delivery: preclinical applications and clinical translation, Expert Opin. Drug Deliv., 12, 1203, 10.1517/17425247.2015.1059420

Kunjachan, 2015, Noninvasive Imaging of Nanomedicines and Nanotheranostics: Principles, Progress, and Prospects, Chem. Rev., 115, 10907, 10.1021/cr500314d

Radomski, 2005, Nanoparticle-induced platelet aggregation and vascular thrombosis, Br. J. Pharmacol., 146, 882, 10.1038/sj.bjp.0706386

Albanese, 2012, The effect of nanoparticle size shape, and surface chemistry on biological systems, Annu. Rev. Biomed. Eng., 14, 1, 10.1146/annurev-bioeng-071811-150124

Alexis, 2008, Factors affecting the clearance and biodistribution of polymeric nanoparticles, Mol. Pharm., 5, 505, 10.1021/mp800051m

Matsumuraand, 1986, A new concept for macromolecular therapeutics in cancer-chemotherapy—mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs, Cancer Res., 46, 6387

Maeda, 2000, Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review, J. Control. Release, 65, 271, 10.1016/S0168-3659(99)00248-5

Kratzand, 2012, Finding the optimal balance: challenges of improving conventional cancer chemotherapy using suitable combinations with nano-sized drug delivery systems, J. Control. Release, 164, 221, 10.1016/j.jconrel.2012.05.045

Chauhan, 2011, Delivery of molecular and nanoscale medicine to tumors: transport barriers and strategies, Annu. Rev. Chem. Biomol., 2, 281, 10.1146/annurev-chembioeng-061010-114300

Fukumuraand, 2007, Tumor microenvironment abnormalities: causes, consequences, and strategies to normalize, J. Cell. Biochem., 101, 937, 10.1002/jcb.21187

Dreher, 2006, Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers, J. Natl. Cancer Inst., 98, 335, 10.1093/jnci/djj070

O'Brien, 2004, Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX (TM)/Doxil (R)) versus conventional doxorubicin for first-line treatment of metastatic breast cancer, Ann. Oncol., 15, 440, 10.1093/annonc/mdh097

Gordon, 2001, Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan, J. Clin. Oncol., 19, 3312, 10.1200/JCO.2001.19.14.3312

Klibanov, 1990, Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes, FEBS Lett., 268, 235, 10.1016/0014-5793(90)81016-H

Harrisand, 2003, Effect of pegylation on pharmaceuticals, Nat. Rev. Drug Discov., 2, 214, 10.1038/nrd1033

Forssenand, 1994, Daunoxome® treatment of solid tumors: preclinical and clinical investigations, J. Liposome Res., 4, 481, 10.3109/08982109409037058

Owen, 2012, Polymeric micelle stability, Nano Today, 7, 53, 10.1016/j.nantod.2012.01.002

Rijcken, 2007, Hydrolysable core-crosslinked thermosensitive polymeric micelles: synthesis, characterisation and in vivo studies, Biomaterials, 28, 5581, 10.1016/j.biomaterials.2007.08.047

Letchfordand, 2007, A review of the formation and classification of amphiphilic block copolymer nanoparticulate structures: micelles, nanospheres, nanocapsules and polymersomes, Eur. J. Pharm. Biopharm., 65, 259, 10.1016/j.ejpb.2006.11.009

Shi, 2015, Complete regression of xenograft tumors upon targeted delivery of paclitaxel via Pi-Pi stacking stabilized polymeric micelles, ACS Nano, 9, 3740, 10.1021/acsnano.5b00929

Letchfordand, 2012, Copolymer micelles and nanospheres with different in vitro stability demonstrate similar paclitaxel pharmacokinetics, Mol. Pharm., 9, 248, 10.1021/mp2002939

Rijcken, 2016

Talelli, 2015, Core-crosslinked polymeric micelles: principles, preparation, biomedical applications and clinical translation, Nano Today, 10, 93, 10.1016/j.nantod.2015.01.005

Park, 2016, Biodegradable inorganic nanovector: passive versus active tumor targeting in siRNA transportation, Angew. Chem. Int. Ed., 55, 4582, 10.1002/anie.201510844

Jin, 2016, Core-shell nanocarriers with high paclitaxel loading for passive and active targeting, Sci. Rep. UK, 6

Guo, 2015, Transferrin-conjugated doxorubicin-loaded lipid-coated nanoparticles for the targeting and therapy of lung cancer, Oncol. Lett., 9, 1065, 10.3892/ol.2014.2840

Liu, 2013, PEG-PLGA Nanoparticle modified by Transferrin Loading Doxorubicin: in vitro and in vivo Studies for Glioma, Adv. Mater. Res. Switz., 750–752, 1643, 10.4028/www.scientific.net/AMR.750-752.1643

Sahooand, 2005, Enhanced antiproliferative activity of transferrin-conjugated paclitaxel-loaded nanoparticles is mediated via sustained intracellular drug retention, Mol. Pharm., 2, 373, 10.1021/mp050032z

Talelli, 2013, Intrinsically active nanobody-modified polymeric micelles for tumor-targeted combination therapy, Biomaterials, 34, 1255, 10.1016/j.biomaterials.2012.09.064

Hrkach, 2012, Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile, Sci. Transl. Med., 4, 10.1126/scitranslmed.3003651

Fiandra, 2013, Assessing the in vivo targeting efficiency of multifunctional nanoconstructs bearing antibody-derived ligands, ACS Nano, 7, 6092, 10.1021/nn4018922

Kirpotin, 2006, Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models, Cancer Res., 66, 6732, 10.1158/0008-5472.CAN-05-4199

Kunjachan, 2014, Passive versus active tumor targeting using RGD- and NGR-modified polymeric nanomedicines, Nano Lett., 14, 972, 10.1021/nl404391r

Zuckerman, 2014, Correlating animal and human phase Ia/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA, Proc. Natl. Acad. Sci. U. S. A., 111, 11449, 10.1073/pnas.1411393111

Senzer, 2013, Phase I study of a systemically delivered p53 nanoparticle in advanced solid tumors, Mol. Ther., 21, 1096, 10.1038/mt.2013.32

Pirollo, 2008, Tumor-targeting nanocomplex delivery of novel tumor suppressor RB94 chemosensitizes bladder carcinoma cells in vitro and in vivo, Clin. Cancer Res., 14, 2190, 10.1158/1078-0432.CCR-07-1951

Tolcher, 2015, Safety and activity of DCR-MYC, a first-in-class Dicer-substrate small interfering RNA (DsiRNA) targeting MYC, in a phase I study in patients with advanced solid tumors, J. Clin. Oncol., 33, 10.1200/jco.2015.33.15_suppl.11006

Muyldermans, 2009, Camelid immunoglobulins and nanobody technology, Vet. Immunol. Immunopathol., 128, 178, 10.1016/j.vetimm.2008.10.299

Koukourakis, 2000, High intratumoral accumulation of stealth liposomal doxorubicin in sarcomas—rationale for combination with radiotherapy, Acta Oncol., 39, 207, 10.1080/028418600430789

Harrington, 2001, Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes, Clin. Cancer Res., 7, 243

Al-Ahmadyand, 2016, Chemical components for the design of temperature-responsive vesicles as cancer therapeutics, Chem. Rev., 116, 3883, 10.1021/acs.chemrev.5b00578

Mura, 2013, Stimuli-responsive nanocarriers for drug delivery, Nat. Mater., 12, 991, 10.1038/nmat3776

Manzoor, 2012, Overcoming limitations in nanoparticle drug delivery: triggered, intravascular release to improve drug penetration into tumors, Cancer Res., 72, 5566, 10.1158/0008-5472.CAN-12-1683

Kiessling, 2014, Nanoparticles for imaging: top or flop?, Radiology, 273, 10, 10.1148/radiol.14131520

Baetke, 2015, Applications of nanoparticles for diagnosis and therapy of cancer, Br. J. Radiol., 88, 10.1259/bjr.20150207

Lammers, 2010, Nanotheranostics and image-guided drug delivery: current concepts and future directions, Mol. Pharm., 7, 1899, 10.1021/mp100228v

Lammers, 2012, Personalized nanomedicine, Clin. Cancer Res., 18, 4889, 10.1158/1078-0432.CCR-12-1414

de Jong, 2014, Imaging preclinical tumour models: improving translational power, Nat. Rev. Cancer, 14, 481, 10.1038/nrc3751

Kunjachan, 2013, Noninvasive optical imaging of nanomedicine biodistribution, ACS Nano, 7, 252, 10.1021/nn303955n

Terreno, 2010, Challenges for molecular magnetic resonance imaging, Chem. Rev., 110, 3019, 10.1021/cr100025t

Onuki, 2010, Noninvasive visualization of in vivo release and intratumoral distribution of surrogate MR contrast agent using the dual MR contrast technique, Biomaterials, 31, 7132, 10.1016/j.biomaterials.2010.06.008

Kokuryo, 2015, Evaluation of thermo-triggered drug release in intramuscular-transplanted tumors using thermosensitive polymer-modified liposomes and MRI, Nanomed. Nanotechnol., 11, 229, 10.1016/j.nano.2014.09.001

Negussie, 2011, Formulation and characterisation of magnetic resonance imageable thermally sensitive liposomes for use with magnetic resonance-guided high intensity focused ultrasound, Int. J. Hyperthermia, 27, 140, 10.3109/02656736.2010.528140

de Smet, 2011, Magnetic resonance imaging of high intensity focused ultrasound mediated drug delivery from temperature-sensitive liposomes: an in vivo proof-of-concept study, J. Control. Release, 150, 102, 10.1016/j.jconrel.2010.10.036

de Smet, 2013, SPECT/CT imaging of temperature-sensitive liposomes for MR-image guided drug delivery with high intensity focused ultrasound, J. Control. Release, 169, 82, 10.1016/j.jconrel.2013.04.005

Ranjan, 2012, Image-guided drug delivery with magnetic resonance guided high intensity focused ultrasound and temperature sensitive liposomes in a rabbit Vx2 tumor model, J. Control. Release, 158, 487, 10.1016/j.jconrel.2011.12.011

van Elk, 2015, Alginate microspheres containing temperature sensitive liposomes (TSL) for MR-guided embolization and triggered release of doxorubicin, PLoS One, 10, 10.1371/journal.pone.0141626

Schleich, 2014, Comparison of active, passive and magnetic targeting to tumors of multifunctional paclitaxel/SPIO-loaded nanoparticles for tumor imaging and therapy, J. Control. Release, 194, 82, 10.1016/j.jconrel.2014.07.059

Xiao, 2012, Multifunctional unimolecular micelles for cancer-targeted drug delivery and positron emission tomography imaging, Biomaterials, 33, 3071, 10.1016/j.biomaterials.2011.12.030